Business Context and Reporting Period
This Form 8-K Current Report was filed by Abbott Laboratories on January 3, 2020. The report addresses Item 5.02 regarding the departure of a senior officer and the appointment of a successor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes.
Material Changes
- Departure: Brian B. Yoor, Executive Vice President, Finance and Chief Financial Officer, announced his retirement effective February 29, 2020.
- Appointment: Robert E. Funck, Jr., 58, was appointed as Executive Vice President, Finance and Chief Financial Officer, effective March 1, 2020.
- Succession Context: Mr. Funck is an internal promotion, having served as Senior Vice President, Finance and Controller since 2018. He joined Abbott in 1987 and has held various finance and compliance roles since 2005.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business performance. Regarding compensation, Mr. Funck will receive a base salary, annual incentive, long-term incentive, and other benefits consistent with similarly situated executive officers, as detailed in the company's 2019 proxy statement.
Investor Verification Checklist
- Verify the exact transition timeline between Mr. Yoor's retirement (Feb 29, 2020) and Mr. Funck's start date (Mar 1, 2020).
- Review the 2019 Proxy Statement (Schedule 14A) for specific details on the compensation plans applicable to the new CFO.
- Confirm Mr. Funck's tenure and prior roles within Abbott to assess continuity in financial leadership.